Search

Displaying results 911 - 920 of 9347 in total
  1. Drug

    Metoprolol

    go.drugbank.com/drugs/DB00264
    ApprovedInvestigational

    [A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. … [T274] To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US.

    Products: Metoprolol Succinate E/r, METOPROLOLINYECCIONBP (1MG/ML)- 5 ML AMPOLLA DE VIDRIO
  2. Drug

    Pizotifen

    go.drugbank.com/drugs/DB06153
    Approved

    Pizotifen belongs to the class of antamines and is related to [cyproheptadine].[A32532] It is a potent serotonin and tryptamine antagonist that has been used for migraine prevention for many years. … Some patients receiving pizotifen treatment developed tolerance with the prolonged use of the drug [L2292].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [A7708]. … for VTE [A27285].

  4. Drug

    Haloperidol

    go.drugbank.com/drugs/DB00502
    ApprovedInvestigational

    be caused by a hyperdopaminergic state within the limbic system of the brain. … (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain.

    Products: HALDOL JANSSEN DECANOAT DE, HALOPERIDOL TABLETAS DE 10 MG
  5. Drug

    Sincalide

    go.drugbank.com/drugs/DB09142
    Approved

    The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. … Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders.

  6. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    Due to the risk of bone fractures that may lead to morbidities and reduced quality of life, the management of osteoporosis in postmenopausal women with the use of therapeutic agents in addition to concurrent … [T28] The main effects of raloxifene are to preserve the bone mineral density and decrease the risk of breast cancer in postmenopausal women.

    Categories: Sex Hormones and Modulators of the Genital System
  7. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. … Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

  8. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the … This action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects

  9. Drug

    Chlortetracycline

    go.drugbank.com/drugs/DB09093
    ApprovedVet approvedWithdrawn

    Chlortetracycline is a _tetracycline_ antibiotic, and historically the first member of this class to be identified. … The organism was named _Streptomyces aureofaciens_ due to its gold-hued color.

  10. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. … [A236359] Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase